Product Information

Strain AVB101, an E. coli B strain (hsdR, lon11, sulA1), contains pBirAcm , an IPTG inducible plasmid containing the BirA gene engineered into pACYC184. It is compatible with most cloning vectors and is maintained with Chloramphenicol (10 µg/ml). This strain is recommended for protein expression because of its robust growth and the absence of the OmpT and Lon proteases.

At the time of induction, Biotin should be added at a concentration of 50 µM. The pAN and pAC vectors containing the AviTag^TM require ampicillin (100 µg/ml).

Cells are supplied as a 0.5 ml liquid culture in 30% glycerol. Store at -80°C.

Note: AVB101 cells are not competent. For BirA expressing competent cells please look at related products.

提供全套的蛋白、肽生物素化的产品，其主要产品包括：生物素蛋白连接酶（BirA）；生物素化菌株；AviTag 载体；生物素化重组蛋白.

Avidity, LLC was founded in 1996 by Millard Cull, Larry Lansing, Dr. Ron Gill, and Dr. Mark Seville to develop peptide tags and molecular biology products based upon the extraordinary affinity of biotin for avidin or streptavidin. While working at Affymax as a researcher, Millard was involved in the discovery of the AviTag technology, saw its commercial potential, and obtained the exclusive rights from Affymax. He started Avidity as a reagent company that sublicenses the right to use the AviTag technology to other companies and sells products for use with the technology.